Skip to main content

Table 1 Patient characteristics

From: Long term outcomes from lymphatic venous anastomosis after total hysterectomy to prevent postoperative lymphedema in lower limb

Case (Facility)

Staging of cancer

BMI

Histology

Postoperative chemotherapy

Survival and observation period (Month)

1 (I)

III A

23.6

CS

IAP

ANED at 102

2 (I)

I A

23.2

EAD Grade1

MPA

ANED at 65

3 (I)

III C1

19.6

EAD Grade2

AP

ANED at 96

4 (I)

I A

22.2

EAD Grade1

MPA

ANED at 157

5 (I)

I A

20.3

EAD Grade1

-

ANED at 127

6 (I)

III C1

20.8

EAD Grade3

AP

ANED at 94

7 (I)

I A

23.4

EAD Grade3

AP

ANED at 163

8 (I)

I A

20.3

EAD Grade1

-

ANED at 154

9 (II)

III C1

20.3

EAD Grade1

TC

Deceased at 115

10 (II)

I A

18.4

EAD Grade3

-

ANED at 136

11 (II)

II

19.6

EAD Grade1

DC

ANED at 65

12 (II)

I A

22.6

EAD Grade2

-

ANED at 120

13 (II)

I B

19

EAD Grade1

DC

Deceased at 118

14 (II)

I A

26.5

EAD Grade1

-

ANED at 62

15 (II)

III A

19.6

EAD Grade2

DC

ANED at 49

16 (II)

I B

19.7

EAD Grade2

DC

ANED at 77

  1. Facility (I): The Jikei University, (II): Saga University; CS: Carcinosarcoma; EAD: Endometrioid adenocarcinoma; IAP: Ifosfamide, farmorubicin, cisplatin; MPA: Medroxyprogesterone acetate; AP: Adriamycin, cisplatin; TC: Paclitaxel, carboplatin; DC: Docetaxel, carboplatin; ANED: Alive with No Evidence of Disease regarding cancer